Targeting the Transforming Growth Factor-beta Signaling in Cancer Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sheen, Yhun Yhong | - |
dc.contributor.author | Kim, Min-Jin | - |
dc.contributor.author | Park, Sang-A | - |
dc.contributor.author | Park, So-Yeon | - |
dc.contributor.author | Nam, Jeong-Seok | - |
dc.date.available | 2020-02-28T22:46:47Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-09-30 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14294 | - |
dc.description.abstract | TGF-beta pathway is being extensively evaluated as a potential therapeutic target. The transforming growth factor-beta (TGF-beta) signaling pathway has the dual role in both tumor suppression and tumor promotion. To design cancer therapeutics successfully, it is important to understand TGF-beta related functional contexts. This review discusses the molecular mechanism of the TGF-beta pathway and describes the different ways of tumor suppression and promotion by TGF-beta. In the last part of the review, the data on targeting TGF-beta pathway for cancer treatment is assessed. The TGF-beta inhibitors in pre-clinical studies, and Phase I and II clinical trials are updated. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC APPLIED PHARMACOLOGY | - |
dc.relation.isPartOf | BIOMOLECULES & THERAPEUTICS | - |
dc.subject | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject | II RECEPTOR GENE | - |
dc.subject | TGF-BETA | - |
dc.subject | KINASE INHIBITOR | - |
dc.subject | CARCINOMA CELLS | - |
dc.subject | BONE METASTASIS | - |
dc.subject | IN-VITRO | - |
dc.subject | MUTATIONS | - |
dc.subject | ANTAGONIST | - |
dc.subject | EXPRESSION | - |
dc.title | Targeting the Transforming Growth Factor-beta Signaling in Cancer Therapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329335600001 | - |
dc.identifier.doi | 10.4062/biomolther.2013.072 | - |
dc.identifier.bibliographicCitation | BIOMOLECULES & THERAPEUTICS, v.21, no.5, pp.323 - 331 | - |
dc.identifier.kciid | ART001808411 | - |
dc.identifier.scopusid | 2-s2.0-84885063519 | - |
dc.citation.endPage | 331 | - |
dc.citation.startPage | 323 | - |
dc.citation.title | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.volume | 21 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Nam, Jeong-Seok | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Transforming growth factor-beta (TGF-beta) | - |
dc.subject.keywordAuthor | EW-7197 | - |
dc.subject.keywordAuthor | ALK5 | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Metastasis | - |
dc.subject.keywordPlus | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject.keywordPlus | II RECEPTOR GENE | - |
dc.subject.keywordPlus | TGF-BETA | - |
dc.subject.keywordPlus | KINASE INHIBITOR | - |
dc.subject.keywordPlus | CARCINOMA CELLS | - |
dc.subject.keywordPlus | BONE METASTASIS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | ANTAGONIST | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.